| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/14/2011 | US20110085993 Use of creatine or creatine compounds for skin preservation |
| 04/14/2011 | US20110085985 Novel substituted azabenzoxazoles |
| 04/14/2011 | US20110085984 Drug Product and Process for Making |
| 04/14/2011 | US20110085981 Glycan-based drugs, therapies and biomarkers |
| 04/14/2011 | US20110085979 Conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions |
| 04/14/2011 | US20110085978 Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors |
| 04/14/2011 | US20110085975 Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof |
| 04/14/2011 | US20110085974 Small molecule ligand-drug conjugates for targeted cancer therapy |
| 04/14/2011 | US20110083991 Hyaluronic acid derivative and drug containing the same |
| 04/14/2011 | US20110083984 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis |
| 04/14/2011 | DE102010044853A1 Hemmung des Überlebens von Hautkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of skin cancer by cyclohexenone from Antrodia camphorata |
| 04/14/2011 | DE102009049662A1 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten 2,5-disubstituted 2H-indazoles as EP2-receptor antagonists |
| 04/14/2011 | CA2784277A1 Pyrazoles derivatives modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| 04/14/2011 | CA2780295A1 Compositions and methods for treating obesity |
| 04/14/2011 | CA2777406A1 Thiazolidinedione energy restriction-mimetic agents |
| 04/14/2011 | CA2777214A1 Methods of treating diseases with proanthocyanidin oligomers such as crofelemer |
| 04/14/2011 | CA2777209A1 Tricyclic and tetracyclic systems with activity on the central-nervous and vascular systems |
| 04/14/2011 | CA2777198A1 Use of toll-like receptor and agonist for treating cancer |
| 04/14/2011 | CA2777185A1 Use of rasagiline for the treatment of progressive supranuclear palsy |
| 04/14/2011 | CA2777114A1 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| 04/14/2011 | CA2777108A1 Sulphone compounds and methods of making and using same |
| 04/14/2011 | CA2777107A1 Antibacterial aminoglycoside analogs |
| 04/14/2011 | CA2777087A1 Combination |
| 04/14/2011 | CA2777085A1 Combination |
| 04/14/2011 | CA2777041A1 Pyrrolidine gpr40 modulators |
| 04/14/2011 | CA2776971A1 Treatment with cholinergic agonists |
| 04/14/2011 | CA2776950A1 Methods for preventing or treating sarcopenia and muscle atrophy in animals |
| 04/14/2011 | CA2776926A1 Androgen treatment in females |
| 04/14/2011 | CA2776921A1 A composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof |
| 04/14/2011 | CA2776847A1 Pyrrolo [3,2 -e] [1,2,4] triazolo [1,5-a] pyrimidines derivatives as inhibitors of microglia activation |
| 04/14/2011 | CA2776844A1 Pyrrolo [3, 2 -e] [1,2,4] triazolo [1,5 -a] pyrimidines derivatives as inhibitors of microglia activation |
| 04/14/2011 | CA2776842A1 Pyrazole derivatives as modulators of calcium release-activated calcium channel |
| 04/14/2011 | CA2776770A1 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| 04/14/2011 | CA2776690A1 Heterocyclic compounds useful as pdk1 inhibitors |
| 04/14/2011 | CA2776308A1 Purine derivatives useful as hsp90 inhibitors |
| 04/14/2011 | CA2776260A1 P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators |
| 04/14/2011 | CA2776242A1 Phenyloxadiazole derivatives as pgds inhibitors |
| 04/14/2011 | CA2776021A1 Sulfonamides for the prevention of diabetes |
| 04/14/2011 | CA2776005A1 Inorganic salt complexes of vildagliptin |
| 04/14/2011 | CA2775902A1 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| 04/14/2011 | CA2775793A1 Siglec 15 antibodies in treating bone loss-related disease |
| 04/14/2011 | CA2775603A1 Carrageenan-containing aqueous antimicrobial compositions |
| 04/14/2011 | CA2775089A1 Low ether composition and delivery apparatus |
| 04/14/2011 | CA2774992A1 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
| 04/14/2011 | CA2774720A1 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| 04/14/2011 | CA2774579A1 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| 04/14/2011 | CA2774573A1 Compounds and compositions as modulators of gpr119 activity |
| 04/14/2011 | CA2774215A1 Bicyclic heterocycles and their use as ccr2 receptor antagonists |
| 04/14/2011 | CA2774133A1 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same |
| 04/14/2011 | CA2773713A1 Novel trpa1 antagonists |
| 04/14/2011 | CA2773676A1 Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof |
| 04/14/2011 | CA2773576A1 Apogossypolone derivatives as anticancer agents |
| 04/14/2011 | CA2773467A1 Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof |
| 04/13/2011 | EP2308996A1 Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis |
| 04/13/2011 | EP2308989A2 Pectin hydrolysis products |
| 04/13/2011 | EP2308963A2 System for processing lipoaspirate cells |
| 04/13/2011 | EP2308885A2 Novel compounds and methods for therapy |
| 04/13/2011 | EP2308883A1 New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria |
| 04/13/2011 | EP2308880A1 Tetracyclic compound |
| 04/13/2011 | EP2308879A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 04/13/2011 | EP2308878A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments |
| 04/13/2011 | EP2308877A1 Imidazopyridin-2-on derivative |
| 04/13/2011 | EP2308876A1 Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists |
| 04/13/2011 | EP2308875A1 Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators |
| 04/13/2011 | EP2308874A1 Useful beta-lactamase inhibitors |
| 04/13/2011 | EP2308873A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| 04/13/2011 | EP2308871A1 Substituted indole compounds and their use as 5-HT6 receptor modulators |
| 04/13/2011 | EP2308870A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses |
| 04/13/2011 | EP2308869A1 Azole compound |
| 04/13/2011 | EP2308868A1 Histone deacetylase inhibitors and uses thereof |
| 04/13/2011 | EP2308867A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses |
| 04/13/2011 | EP2308864A1 Pharmaceutical formulation of duloxetine hydrochloride |
| 04/13/2011 | EP2308863A1 7-substituted fused ring tetracycline compounds |
| 04/13/2011 | EP2308861A1 Macrocyclic compounds useful as pharmaceuticals |
| 04/13/2011 | EP2308860A1 Immunosuppressor based on the interruption of tcr-nck interaction |
| 04/13/2011 | EP2308855A1 2,4-Diaminopyrimidine derivatives |
| 04/13/2011 | EP2308854A1 2,3,6-trisubstituted-4-pyrimidone derivatives |
| 04/13/2011 | EP2308852A1 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors |
| 04/13/2011 | EP2308851A1 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes |
| 04/13/2011 | EP2308850A1 Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments |
| 04/13/2011 | EP2308849A1 Indane-amine derivatives, their preparation and use as medicaments |
| 04/13/2011 | EP2308848A1 Quinoline-derived amide modulators of vanilloid VR1 receptor |
| 04/13/2011 | EP2308847A1 Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
| 04/13/2011 | EP2308846A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308845A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308844A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308842A1 Pharmaceutical compositions |
| 04/13/2011 | EP2308841A2 Phlorizin analogs as SGLT2 inhibitors |
| 04/13/2011 | EP2308840A1 GPCR agonists |
| 04/13/2011 | EP2308839A1 Fused heterocyclic compounds |
| 04/13/2011 | EP2308838A1 Nitrogen-containing aromatic heterocyclyl compound |
| 04/13/2011 | EP2308833A2 Cyclic protein tyrosine kinase inhibitors |
| 04/13/2011 | EP2308832A1 9-Substituted minocycline compounds |
| 04/13/2011 | EP2308830A1 Acid addition salts of 5-aminolevulinic acid or its derivatives |
| 04/13/2011 | EP2308828A2 CaSR antagonist |
| 04/13/2011 | EP2308812A2 N-acylsulfonamide apoptosis promoters |
| 04/13/2011 | EP2308563A1 Risedronic acid for treatment and prevention of bone resorption diseases |
| 04/13/2011 | EP2308562A2 Azetidine ring compounds and drugs comprising the same |
| 04/13/2011 | EP2308515A1 Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
| 04/13/2011 | EP2308512A1 Water-containing composition |